Valuation: SELLAS Life Sciences Group, Inc.

Market Cap 2.29B 2.05B 1.89B 1.72B 3.21B 218B 3.26B 22.8B 9.02B 114B 8.6B 8.41B 361B P/E 2026 *
-55.3x
P/E 2027 * -119x
Enterprise Value 2.29B 2.05B 1.89B 1.72B 3.21B 218B 3.26B 22.8B 9.02B 114B 8.6B 8.41B 361B EV / Sales 2026 *
-
EV / Sales 2027 * 43.1x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SELLAS Life Sciences Group, Inc.

1 day+3.31%
1 week-2.00%
Current month-4.63%
1 month+1.29%
3 months+8.35%
6 months+140.57%
Current year+211.41%
1 week 11.08
Extreme 11.08
12.37
1 month 9.75
Extreme 9.7501
12.7
Current year 3.23
Extreme 3.23
15.88
1 year 1.39
Extreme 1.39
15.88
3 years 0.5
Extreme 0.4986
15.88
5 years 0.5
Extreme 0.4986
15.88
10 years 0.5
Extreme 0.4986
554.5
Manager TitleAgeSince
Chief Executive Officer 50 2017-12-28
Director of Finance/CFO 41 2017-12-29
Compliance Officer - -
Director TitleAgeSince
Director/Board Member 50 2017-12-28
Chairman 66 2024-05-31
Director/Board Member 69 2017-12-28
Date Insider Type Main position Quantity % Market Cap. Importance
1/7/26 Free

Executive/Senior Manager

300,000 0.2106%
1/7/26 Free

Director

50,000 0.0351%
1/7/26 Free

Chief Financial Officer

300,000 0.2106%
Change 5-day change 1-year change 3-year change Capi.($)
+3.35%-2.00%+505.15%+1,154.81% 2.29B
-3.10%-3.43%+36.29%+67.69% 65.28B
0.00%+0.05%+9.85%+77.57% 54.57B
-0.05%+1.38%+9.51%+101.40% 53.59B
+0.79%+2.48%+26.24%+52.54% 45.03B
-2.46%-5.35%+15.37%+113.50% 42.17B
+0.74%-5.04%+221.85%+902.90% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.20%+15.33%+60.48%+49.53% 26.5B
Average -0.27%+2.11%+92.24%+256.48% 38.56B
Weighted average by Cap. -0.73%+1.46%+46.12%+161.44%

Financials

2026 *2027 *
Net sales - 53.09M 47.48M 43.92M 39.77M 74.43M 5.05B 75.65M 529M 209M 2.64B 199M 195M 8.37B
Net income -38.3M -34.24M -31.68M -28.69M -53.69M -3.64B -54.57M -381M -151M -1.91B -144M -141M -6.03B -21.38M -19.11M -17.68M -16.01M -29.97M -2.03B -30.46M -213M -84.18M -1.06B -80.23M -78.52M -3.37B
Net Debt - -
Projected Income Statement - Annual - SELLAS Life Sciences Group, Inc.
Logo SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Employees
-
Date Price Change Volume
26-10-27 US$11.70 +3.18% 1,161,991
26-10-26 US$11.34 -1.73% 3,214,377
26-10-23 US$11.54 +1.67% 3,279,155
26-10-22 US$11.35 -6.51% 6,512,781
26-10-21 US$12.14 +1.34% 5,657,050
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - SELLAS Life Sciences Group, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.34USD
Average target price
32.50USD
Spread / Average Target
+186.60%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SELLAS Life Sciences Group, Inc.